Precision Therapeutics, Forged by Evolution
Cutting-edge research aimed at improving treatment of GI diseases
Our Approach
Building Upon Nature
to Improve Global Health
Kissaki Biosciences is developing novel approaches
to treat gastrointestinal disorders, including:
- Inflammatory bowel disease
- Infectious Diarrhea
Our innovative precision therapies are inspired by natural
products and primarily target gut dysbiosis.
Our Pipeline
Meet the Kissaki Team
Our team capitalizes on decades of drug development experience to
accelerate our treatments to and through the clinic.
Our Scientific Advisory Board
We are pleased to have the guidance and advice of the following
distinguished scientists and business leaders:
Dr. Chris Burns, former Founder and CEO of Venatorx, a recognized world leader in antibacterial and antiviral drug research. Prior to Venatorx, Dr. Burns was at Protez (acquired by Novartis), Viro Pharma, and Sanofi.
Dr. Mark Pykett, CEO of Orogen, a leader in target specific DEL libraries, and former CEO of Myrtelle and Agilis (developer of Upstaza™ and Kebilidi™, and acquired by PTC Therapeutics), CSO of PTC Therapeutics, among other companies.
Dr. Brad Connor, Clinical Professor of Medicine at Weill Cornell Medical College, and a leading specialist in the diagnosis and treatment of gastrointestinal diseases such as IBD, and clinical research in travel medicine and infectious diseases.
About us
The Story & Purpose
Behind Our Name
Gorō Nyūdō Masamune was a medieval Japanese blacksmith
widely acclaimed as Japan’s greatest swordsmith.
In keeping with this tradition of excellence and innovation, we
chose the name Kissaki, which in Japanese, means the “tip of the
sword” or “cutting edge”. The hunt for cutting edge technologies
to treat human diseases is the core of our mission.
Innovation
Our Technology
We engineer disease targeting miniature proteins, based on biosynthetically engineered lasso peptides, to create potent therapeutics.
Inflammatory
Bowel Disease
Ulcerative Colitis (UC) and Crohn’s Disease (CD) are the major forms of Inflammatory Bowel Disease (IBD). Despite the large number of FDA and EMA-approved therapeutics, the unmet medical need remains high, and new therapeutics are needed.
Infectious Diarrhea
Infectious Diarrhea (ID) is a global health problem with lethal consequences for children in developing nations. Healthy adults are also affected as travelers to countries where ID is endemic, because they lack previous exposure and immunity to the causative agent.
Get in Touch With Us
Fill out this form to contact Kissaki Biosciences